BR9601276A - Solução de interferona aquosa - Google Patents

Solução de interferona aquosa

Info

Publication number
BR9601276A
BR9601276A BR9601276A BR9601276A BR9601276A BR 9601276 A BR9601276 A BR 9601276A BR 9601276 A BR9601276 A BR 9601276A BR 9601276 A BR9601276 A BR 9601276A BR 9601276 A BR9601276 A BR 9601276A
Authority
BR
Brazil
Prior art keywords
interferon solution
aqueous interferon
aqueous
solution
interferon
Prior art date
Application number
BR9601276A
Other languages
English (en)
Inventor
Guenter Gross
Sabino Del Terzo
Saran Kandakuri Kumar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9601276A publication Critical patent/BR9601276A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
BR9601276A 1995-04-06 1996-04-04 Solução de interferona aquosa BR9601276A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (1)

Publication Number Publication Date
BR9601276A true BR9601276A (pt) 1998-01-13

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9601276A BR9601276A (pt) 1995-04-06 1996-04-04 Solução de interferona aquosa

Country Status (32)

Country Link
US (1) US5762923A (pt)
EP (1) EP0736303B1 (pt)
JP (1) JP2758154B2 (pt)
KR (1) KR100212346B1 (pt)
CN (1) CN1066065C (pt)
AR (1) AR002932A1 (pt)
AT (1) ATE183650T1 (pt)
AU (1) AU685356B2 (pt)
BR (1) BR9601276A (pt)
CA (1) CA2172664C (pt)
CO (1) CO4750807A1 (pt)
CY (1) CY2194B1 (pt)
CZ (1) CZ287626B6 (pt)
DE (1) DE69603894T2 (pt)
DK (1) DK0736303T3 (pt)
ES (1) ES2136910T3 (pt)
GR (1) GR3031775T3 (pt)
HK (1) HK1012232A1 (pt)
HU (1) HU227643B1 (pt)
IL (1) IL117752A (pt)
MA (1) MA23838A1 (pt)
MY (1) MY113594A (pt)
NO (1) NO316801B1 (pt)
NZ (1) NZ286300A (pt)
PE (1) PE38897A1 (pt)
PL (1) PL183873B1 (pt)
RU (1) RU2113845C1 (pt)
SA (1) SA96160728B1 (pt)
SG (1) SG52806A1 (pt)
TR (1) TR199600287A2 (pt)
TW (1) TW426523B (pt)
ZA (1) ZA962553B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR20000069664A (ko) * 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
TWI243057B (en) * 1998-03-26 2005-11-11 Schering Corp Formulations for protection of peg-interferon alpha conjugates
PT1069912E (pt) * 1998-04-03 2007-09-14 Novartis Vaccines & Diagnostic Formulações injectáveis de igf contendo succinato como agente tampão
CZ300540B6 (cs) 1998-05-15 2009-06-10 Schering Corporation Farmaceutický prostredek obsahující ribavirin v kombinaci s interferonem alfa pro lécbu pacientu s chronickou infekcí hepatitidy C genotypu 1
PL192364B1 (pl) * 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CA2338665C (en) 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2356010A1 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
CN1390132A (zh) 1999-04-08 2003-01-08 先灵公司 聚乙二醇化干扰素α在黑素瘤治疗中的应用
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
HU228583B1 (en) 2000-11-07 2013-04-29 Novartis Vaccines & Diagnostic Stabilized interferon compositions
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AU2003235401B2 (en) 2002-05-21 2008-09-25 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
KR101105486B1 (ko) 2003-04-02 2012-01-13 아레스 트레이딩 에스.에이. Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
JP4871124B2 (ja) 2003-06-20 2012-02-08 アレス トレーディング ソシエテ アノニム 凍結乾燥ｆｓｈ／ｌｈ製剤
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
JP2007538048A (ja) 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
WO2005117948A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
JP4988562B2 (ja) * 2004-06-01 2012-08-01 アレス トレーディング ソシエテ アノニム 安定化したインターフェロン液体製剤
DE602005022895D1 (de) 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
BRPI0514408B8 (pt) * 2004-08-24 2021-05-25 Asubio Pharma Co Ltd preparação liquida de peptídeo fisiologicamente ativo
ES2856881T3 (es) 2005-04-11 2021-09-28 Horizon Pharma Rheumatology Llc Formas variantes de urato oxidasa y su uso
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Pharmaceutical compositions of bupropion
SG177982A1 (en) 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
US8597634B2 (en) * 2007-09-04 2013-12-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha-2a modified by polyethylene glycol and methods of preparation thereof
PT2186830E (pt) * 2007-09-04 2012-06-20 Biosteed Gene Expression Tech Co Ltd Interferão alfa 2b modificado com polietilenoglicol e método de preparação e aplicações do mesmo
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
BRPI0821029A2 (pt) 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
EP2344201A1 (en) * 2008-09-17 2011-07-20 Nektar Therapeutics Oligomer-protease inhibitor conjugates
AU2010265964B2 (en) 2009-06-25 2014-09-18 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016046101A1 (en) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
WO1990005535A1 (en) * 1988-11-14 1990-05-31 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
CA2033714A1 (en) * 1990-01-25 1991-07-26 Alberto Ferro Pharmaceutical preparations
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon

Also Published As

Publication number Publication date
NO961322D0 (no) 1996-04-01
HUP9600857A3 (en) 1998-01-28
HU9600857D0 (en) 1996-05-28
DK0736303T3 (da) 2000-01-10
CN1141808A (zh) 1997-02-05
PL183873B1 (pl) 2002-07-31
RU2113845C1 (ru) 1998-06-27
CY2194B1 (en) 2002-11-08
JP2758154B2 (ja) 1998-05-28
ES2136910T3 (es) 1999-12-01
IL117752A (en) 2000-11-21
AU685356B2 (en) 1998-01-15
CZ99496A3 (en) 1996-10-16
AR002932A1 (es) 1998-05-27
GR3031775T3 (en) 2000-02-29
TR199600287A2 (tr) 1997-03-21
HK1012232A1 (en) 1999-07-30
ATE183650T1 (de) 1999-09-15
JPH08283176A (ja) 1996-10-29
IL117752A0 (en) 1996-08-04
NO316801B1 (no) 2004-05-18
SA96160728B1 (ar) 2005-05-04
NO961322L (no) 1996-10-07
MA23838A1 (fr) 1996-12-31
TW426523B (en) 2001-03-21
CN1066065C (zh) 2001-05-23
CA2172664C (en) 2000-10-03
CO4750807A1 (es) 1999-03-31
DE69603894D1 (de) 1999-09-30
AU5044696A (en) 1996-10-17
CZ287626B6 (en) 2001-01-17
ZA962553B (en) 1996-10-07
KR100212346B1 (ko) 1999-08-02
CA2172664A1 (en) 1996-10-07
EP0736303A2 (en) 1996-10-09
EP0736303B1 (en) 1999-08-25
MY113594A (en) 2002-04-30
HU227643B1 (en) 2011-10-28
PE38897A1 (es) 1997-10-04
DE69603894T2 (de) 2000-04-20
KR960037063A (ko) 1996-11-19
US5762923A (en) 1998-06-09
PL313655A1 (en) 1996-10-14
NZ286300A (en) 1997-05-26
SG52806A1 (en) 1998-09-28
HUP9600857A2 (en) 1997-08-28
EP0736303A3 (en) 1997-02-26

Similar Documents

Publication Publication Date Title
BR9601276A (pt) Solução de interferona aquosa
DE59606873D1 (de) Spezialanzug
PT833828E (pt) Derivados de rapamicina
DK0822982T3 (da) Cyclomaltodextringlucanotransferasevarianter
BR9609682A (pt) Foto-desinfetantes de baixa nuança
BR9611834A (pt) Derivados de oximetóxi-3-aril-pirona
BR9605434A (pt) Derivados de purin-6-ona
DE59605335D1 (de) Muldenkörper
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
PT856007E (pt) Derivados de ciclopeptidos
BR9610597A (pt) Derivados de diarilalcenilamina
BR9607535A (pt) Arabinofuranodidase de aspergillus
BR9603508A (pt) Derivados de alquenil-benzoilguanidina
PT843675E (pt) Derivados de aza-antraciclinona
PT839024E (pt) Formulacoes de monensina
DK0827503T3 (da) Pyrrolidinylmethylindol-salt
DE59708205D1 (de) Wässrige bleichmittel
DE69513898D1 (de) Distanzstück
KR970005583U (ko) 자동차의 하부 차체
KR970005590U (ko) 차체의 크로스멤버
KR960028332U (ko) 시신관
KR970033137U (ko) 자동점멸장치
ID16384A (id) Larutan interferon
KR970009598U (ko) 캔 스트롱
BR7500505U (pt) Amolador de facas

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 20A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.